An industry veteran reveals that payers, wanting to keep their patient members happy, are highly sensitive to public demand. Pharmaceutical companies can leverage this by generating significant patient and physician interest, which pressures payers into providing more favorable formulary coverage.

Mark Cuban argues that while policy helped, the most significant factor in the recent historic drop in drug prices was the introduction of biosimilars—generic versions of expensive injectable drugs. For example, Humira's price plummeted from $8,000 to $400 a month on his platform due to this new competition.

SmithRx CEO Jake Friends argues that new PBM transparency laws fail. The proof is that the stocks of the large, regulated PBMs rose after the legislation passed, as markets understood that profit pools would simply shift and the laws would increase barriers to entry for competitors.

By forcing disclosure of the lowest net price, MFN could dismantle the system of confidential rebates. This is a problem for payers (health plans, PBMs) who use their ability to negotiate superior, secret rebates as a key competitive advantage. A transparent system creates a level playing field, eroding this value proposition.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

To solve the insulin price bubble, Eli Lilly launched its own low-list-price biosimilar. However, insurers and PBMs initially refused to cover it because its low price and small rebate threatened their lucrative business model.

Smaller biotech firms face significant hurdles in gaining market access. They often cannot negotiate directly with Pharmacy Benefit Managers (PBMs) for formulary placement. Instead, they must use a third-party negotiator representing multiple small companies, a process that is opaque and can cause critical launch delays.

The large gap between insulin's list and net price was driven by Pharmacy Benefit Managers (PBMs). Their business model, which takes a percentage of the rebate, incentivized pharma to raise list prices to offer bigger discounts.

Beyond low-cost generic drugs, Cuban's company negotiates directly with hospitals for better prices. The truly disruptive move is publishing this transparent contract online (at costpluswellness.com), empowering any self-insured business to bypass insurance middlemen and access the same pre-negotiated rates.